Insect cell-derived rHA (RIV4) has been studied extensively b
various groups in both pre-clinical models and humans. The rH
containedinRIV4differs fromthatexpressedinother systemsi
terms of specific structural features, the nature of the sourc
materialandthemanufacturingprocess,whichhaveanimpacto
certain aspects of vaccine safety and efficacy (Fig. 2). Based o
these unique features, RIV4 received ‘product exclusivity’ protec
tion from FDA, a ‘new active substance’ designation from EM
Committee for Medicinal Products for Human Use (CHMP)48 an
an‘innovativedrug’designationfromHealthCanada49.Theuseo
this technology, together with the molecular characterisation o
the product, should facilitate continued evolution of influenz
vaccines with improved effectivenessand theirtimely availabilit